2026-01-25
minor
Study Identification, Study Status, Study Description, Arms and Interventions, Outcome Measures, Eligibility v1
InterventionsIMM0306 2.0mg/kg (Drug), Lenalidomide 20 mg (Drug), Placebo (Drug)→IMM0306 2.0 mg/kg (Drug), Lenalidomide 20 mg (Drug), Placebo (Drug)
Eligibility criteria-47 characters
[...] riteria).
Histologically confirmed CD20-positive Follicular lymphomaLymphoma, Grade 1, 2, or 3a.
Previously received at least two prior systemic regimenregimens, including at least one line containing an anti-CD20 monocl [...] hematologic, and renal function.
Expected survival at least≥ 6 months.
Exclusion Criteria:
Autologous HSCT within 100 da [...] s.
Severe organic cardiovascular or cerebrovascular diseases, or active infection requiring systemic therapy.
History of severe allergic reactions to any components of [...]
Secondary endpoints7 entries, revised
Complete remission rate(CRR) as Assessed by Independent YReviewReview Committee(IRC)
Study titlerevised
IMM0306 in Combination With Lenalidomide VSvs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma